2/4
08:00 am
akba
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Low
Report
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
2/2
04:05 pm
akba
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/13
01:39 pm
akba
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts [Seeking Alpha]
Low
Report
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts [Seeking Alpha]
1/12
08:27 am
akba
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook [Yahoo! Finance]
Medium
Report
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook [Yahoo! Finance]
1/12
08:00 am
akba
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
Medium
Report
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
1/7
08:51 am
akba
Akebia announces first patient dosed in Phase 2 trial of praliciguat [Yahoo! Finance]
Low
Report
Akebia announces first patient dosed in Phase 2 trial of praliciguat [Yahoo! Finance]
1/6
08:00 am
akba
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
Low
Report
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
1/5
04:05 pm
akba
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/28
12:57 pm
akba
Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat [Yahoo! Finance]
Low
Report
Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat [Yahoo! Finance]
12/11
06:39 am
akba
Analysts Are Optimistic We'll See A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA) [Yahoo! Finance]
Medium
Report
Analysts Are Optimistic We'll See A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA) [Yahoo! Finance]
12/2
11:00 am
akba
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $5.00 price target on the stock.
Low
Report
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $5.00 price target on the stock.
12/2
08:04 am
akba
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
12/1
04:05 pm
akba
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/1
07:00 am
akba
Akebia Announces Establishment of Rare Kidney Disease Pipeline
Medium
Report
Akebia Announces Establishment of Rare Kidney Disease Pipeline
11/24
08:00 am
akba
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
11/14
02:40 am
akba
Why Is Akebia (AKBA) Up After Strong Vafseo Data and Surging Q3 2025 Revenue? [Yahoo! Finance]
Medium
Report
Why Is Akebia (AKBA) Up After Strong Vafseo Data and Surging Q3 2025 Revenue? [Yahoo! Finance]
11/12
06:23 am
akba
Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]
Low
Report
Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]
11/10
07:11 am
akba
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
11/10
07:00 am
akba
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
High
Report
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
11/6
07:03 pm
akba
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs [Yahoo! Finance]
Medium
Report
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs [Yahoo! Finance]
11/6
06:30 pm
akba
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs
Low
Report
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs